[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.119.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 14,969
Citations 0
Medical News & Perspectives
November 15, 2016

A Precision Medicine Approach to Clinical Trials

JAMA. 2016;316(19):1953-1955. doi:10.1001/jama.2016.12137

Five or 6 years ago, only 5% to 10% of patients at David Hong, MD,’s clinic arrived with a mutational profile of their tumor. Today, it’s more like 25% to 30%. They come bearing their tumor profile in the hope that they’ll qualify for one of a growing number of clinical trials targeting specific biomarkers, a strategy called precision medicine. Desperate, some come already knowing that they qualify for a particular trial, thanks to Facebook groups for cancer patients whose tumors share the same genetic abnormality and other online resources.

First Page Preview View Large
First page PDF preview
First page PDF preview
×